218例尘肺结核分期化疗方案的临床研究

摘要/Abstract

摘要： 目的探讨尘肺结核菌阳初治患者根据尘肺分期使用不同疗程化疗方案的近远期疗效。方法按尘肺分期及病灶范围分为4组（A₁、A₂、B₁、B₂）给予不同的化疗方案，全程督导治疗结束并随访5年。考核痰菌的阴转率、复阳率，并进行各组间比较。结果4组病例化疗疗程结束痰菌阴转率达到100%，随访5年期间痰菌复阳率分别为17.4%、4.3%、22.5%、5.0%。结论A₂组方案3HRZS(E)/6HRZ/9HRE适用于Ⅰ～Ⅱ期尘肺结核，B₂组方案3HRZS(E)/9HRZ/12HRE适用于Ⅲ期尘肺结核，对该组方案的远期疗效满意。

关键词: 矽肺结核/药物疗法, 临床方案

Abstract: ObjectiveTo investigate the short-term and long-term therapeutic effects of different chemotherapeutic regimens for silicosis patients with initial smear positive pulmonary tuberculosis in different stages. MethodsAccording to silicosis stages and lesions distribution, 218 initial treated smear-positive Silicotuberculosis patients were divided into four groups (A1, A2, B1, B2) and received different chemotherapeutic regimens. All patients were supervised to finish chemotherapy and then followed up for 5 years. The rates of sputum negative conversion and relapse were observed. ResultsAt the end of full treatment courses, the sputum negative conversion rates in all groups were 100%. During the five-year follow-up, the sputum re-positive rates in A1 group、A2 group、B1 group、B2 group were 14.3%, 3.8%, 11.4% and 4.7% respectively. ConclusionsThe chemotherapeutic regimen with 3HRZS(E)/6HRZ/9HRE fits to treat Silicotuberculosis in stageⅠ-Ⅱ.The chemotherapeutic regimen with 3HRZS(E)/9HRZ/12HRE fits to treat Silicotuberculosis in stage Ⅲ, and the long-term effect of this group's chemotherapy is satisfactory.

Key words: silicotuberculosis/drug therapy, clinical protocols

余中英,王挺,刘耀松,王文炳. 218例尘肺结核分期化疗方案的临床研究[J]. 中国防痨杂志, 2009, 31(11): 657-659.

Yu Zhongying，Wang Ting, Liu Yaosong，Wang Wenbin.. A clinical study on chemotherapy in 218 cases of Silicotuberculosis in different stages[J]. Chinese Journal of Antituberculosis, 2009, 31(11): 657-659.

[1]	赵本南, 刘大凤, 刘亚玲, 杨铭, 兰丽娟, 杜清. 含丙硫异烟胺和对氨基水杨酸方案治疗耐多药结核病患者致甲状腺功能减退症的临床分析[J]. 中国防痨杂志, 2020, 42(5): 465-471.
[2]	《耐药脊柱结核临床诊疗专家共识》编写组. 耐药脊柱结核临床诊疗专家共识[J]. 中国防痨杂志, 2019, 41(4): 377-382.
[3]	范琳,熊坤龙,肖和平. 建国70年来结核病化学治疗的历史进程要览[J]. 中国防痨杂志, 2019, 41(11): 1145-1148.
[4]	孙雯雯,楼海,孙勤. 含利福布汀方案治疗缓慢生长型非结核分枝杆菌肺病的短期疗效分析[J]. 中国防痨杂志, 2018, 40(9): 948-953.
[5]	金龙,胡卫华,卢水华. 糖尿病对耐多药肺结核的影响与对策[J]. 中国防痨杂志, 2018, 40(9): 999-1002.
[6]	王茂军,马丙乾,郝俊玲,付志华,董淑敏,曹艳竹. 不同方案治疗单耐异烟肼或利福平肺结核患者的预后分析[J]. 中国防痨杂志, 2018, 40(3): 286-291.
[7]	方勇，肖和平. 潜伏性结核感染的诊治进展[J]. 中国防痨杂志, 2016, 38(2): 144-147.
[8]	杜鹃，田丹，陈国玺，姚芳，陈俊，兰星，袁保东. 初治涂阳肺结核患者采用含氟喹诺酮类药物治疗方案的疗效分析[J]. 中国防痨杂志, 2016, 38(11): 968-972.
[9]	刘一典编译沙巍审校. 使用含替加环素方案挽救性治疗52例脓肿分枝杆菌和龟分枝杆菌感染的临床经验 [J]. 中国防痨杂志, 2015, 37(9): 991-991.
[10]	艾静文，阮巧玲，张文宏. 结核分枝杆菌潜伏感染预防性治疗的进展[J]. 中国防痨杂志, 2015, 37(1): 80-85.
[11]	中国防痨协会结核病临床专业委员会. 结核病临床诊治进展年度报告（2013年）（第二部分结核病临床治疗）[J]. 中国防痨杂志, 2014, 36(9): 830-854.
[12]	肖和平，方勇，范琳，刘一典. 耐药结核病化学治疗研究的过去、现状与未来[J]. 中国防痨杂志, 2014, 36(8): 634-637.
[13]	唐神结，刘一典，张占军，肖和平，万利亚. 选择耐多药结核病化疗方案的若干问题[J]. 中国防痨杂志, 2014, 36(7): 521-524.
[14]	丁晓艳，许卫国，竺丽梅，周扬，邵燕，宋红焕，潘洪秋，凌素萍，孙建胜，吴云亮，顾欣荣，陆峰，陆伟. 175例耐多药肺结核患者治疗转归情况分析[J]. 中国防痨杂志, 2014, 36(4): 238-243.
[15]	刘二勇，成诗明，赖钰基，王冬梅，李涛，王黎明，王倪，徐晓玉，周林. 结核病预防性治疗研究进展[J]. 中国防痨杂志, 2014, 36(1): 59-63.

218例尘肺结核分期化疗方案的临床研究

A clinical study on chemotherapy in 218 cases of Silicotuberculosis in different stages

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

友情链接